Literature DB >> 7907421

Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation.

A Samanta1, C M LeVea, W C Dougall, X Qian, M I Greene.   

Abstract

The neu protooncogene (also known as c-erbB2, NGL, and HER2) encodes a 185-kDa transmembrane glycoprotein with intrinsic tyrosine kinase activity that resembles the receptor for epidermal growth factor. The p185 gene and protein were originally identified in the brain and are thought to play a critical role in neurogenesis. Aberrant c-erbB2 protein overexpression also occurs in several human adenocarcinomas. A ligand for p185, neu-activating factor (NAF), specifically binds to neu receptor and increases the p185c-neu tyrosine phosphorylation in vitro and in vivo in a dose-dependent manner. We now show that NAF specifically binds to purified p185 expressed in baculovirus. Direct binding analysis showed that NAF binds with high affinity (Kd = 1.3 nM). We have investigated changes in the structure and association state of baculovirus-produced neu holoreceptor that are induced by ligand binding. In this study, we used sucrose gradients to show that purified p185c-neu exists mainly in the monomeric form at low concentrations, whereas at higher concentrations p185c-neu exists as dimers or multimers. At low concentrations, but in the presence of ligand, p185c-neu sediments as a dimeric or multimeric form. Monomer-oligomer interconversion is absolutely ligand dependent at low receptor concentrations. The high molecular weight form of the receptor is enzymatically more active, as a consequence of ligand-driven activation of the receptor kinase. Oncogenic p185neu receptors sediment predominantly as high molecular weight forms and have constitutively active kinases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7907421      PMCID: PMC43233          DOI: 10.1073/pnas.91.5.1711

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  High-yield trapping of EGF-induced receptor dimers by chemical cross-linking.

Authors:  B O Fanger; J E Stephens; J V Staros
Journal:  FASEB J       Date:  1989-01       Impact factor: 5.191

2.  Growth factor control of epidermal growth factor receptor kinase activity via an intramolecular mechanism.

Authors:  J G Koland; R A Cerione
Journal:  J Biol Chem       Date:  1988-02-15       Impact factor: 5.157

3.  Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation.

Authors:  Y Yarden; J Schlessinger
Journal:  Biochemistry       Date:  1987-03-10       Impact factor: 3.162

4.  Stage- and tissue-specific expression of the neu oncogene in rat development.

Authors:  Y Kokai; J A Cohen; J A Drebin; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

Review 5.  Nerve growth factor revisited.

Authors:  R A Bradshaw; T L Blundell; R Lapatto; N Q McDonald; J Murray-Rust
Journal:  Trends Biochem Sci       Date:  1993-02       Impact factor: 13.807

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  Mechanism of epidermal growth factor receptor autophosphorylation and high-affinity binding.

Authors:  M Böni-Schnetzler; P F Pilch
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

8.  Evidence that receptor aggregation may play a role in transmembrane signaling through the insulin-like growth factor-I receptor.

Authors:  N Ikari; H Yoshino; A C Moses; J S Flier
Journal:  Mol Endocrinol       Date:  1988-09

9.  Affinity labeling and partial purification of nerve growth factor receptors from rat pheochromocytoma and human melanoma cells.

Authors:  P M Grob; C H Berlot; M A Bothwell
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

10.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

Authors:  C R King; M H Kraus; S A Aaronson
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

View more
  21 in total

1.  Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains.

Authors:  R Murali; P J Brennan; T Kieber-Emmons; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  Heregulin-beta promotes matrix metalloproteinase-7 expression via HER2-mediated AP-1 activation in MCF-7 cells.

Authors:  Guogang Yuan; Lu Qian; Lun Song; Ming Shi; Dan Li; Ming Yu; Meiru Hu; Beifen Shen; Ning Guo
Journal:  Mol Cell Biochem       Date:  2008-07-04       Impact factor: 3.396

3.  Bivalence of EGF-like ligands drives the ErbB signaling network.

Authors:  E Tzahar; R Pinkas-Kramarski; J D Moyer; L N Klapper; I Alroy; G Levkowitz; M Shelly; S Henis; M Eisenstein; B J Ratzkin; M Sela; G C Andrews; Y Yarden
Journal:  EMBO J       Date:  1997-08-15       Impact factor: 11.598

Review 4.  Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers.

Authors:  Janakiraman Subramanian; Archana Katta; Ashiq Masood; Dashavantha Reddy Vudem; Rama Krishna Kancha
Journal:  Oncologist       Date:  2019-07-10

5.  ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells.

Authors:  Rebecca S Muraoka; Anne E G Lenferink; Brian Law; Elizabeth Hamilton; Dana M Brantley; L Renee Roebuck; Carlos L Arteaga
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

6.  A kinase associated with chromatin that can be activated by ligand-p185c-Neu or epidermal growth factor-receptor interactions.

Authors:  A Samanta; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

7.  Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells.

Authors:  D M O'Rourke; G D Kao; N Singh; B W Park; R J Muschel; C J Wu; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

8.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

9.  Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells.

Authors:  Sarah E Seton-Rogers; Yu Lu; Lisa M Hines; Malvika Koundinya; Joshua LaBaer; Senthil K Muthuswamy; Joan S Brugge
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-22       Impact factor: 11.205

10.  ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells.

Authors:  G Valabrega; F Fagioli; S Corso; E Madon; A Brach del Prever; E Biasin; A Linari; M Aglietta; S Giordano
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.